| 000 | 02454na a2200373 4500 | ||
|---|---|---|---|
| 999 |
_c3392 _d3392 |
||
| 003 | PC3392 | ||
| 005 | 20191025093841.0 | ||
| 008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_aGhanem Cañete, Ismael _91793 _eOncología Médica |
||
| 245 | 0 | 0 |
_aRC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. _h[artículo] |
| 260 |
_bBreast cancer research and treatment, _c2013 |
||
| 300 | _a138(2):427-35. | ||
| 500 | _aFormato Vancouver: Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D et al. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr;138(2):427-35. | ||
| 501 | _aPMID: 23479422 | ||
| 504 | _a Contiene 32 referencias | ||
| 520 | _aLapatinib adds to the efficacy of trastuzumab in preclinical models and also in the neo-adjuvant setting. This study assesses the safety and feasibility of adding lapatinib to paclitaxel and trastuzumab (THL) as part of the adjuvant therapy for HER2-positive breast cancer (HER2+ BC). In this single-arm phase II study, patients with stages I-III HER2+ BC received standard anthracycline-based chemotherapy followed by weekly taxane, with concurrent standard trastuzumab, plus daily lapatinib for a total of 12 months. The primary endpoint was symptomatic congestive heart failure, secondary endpoints included overall safety. A total of 109 eligible patients were enrolled. Median follow-up is 4.3 years. No patients experienced congestive heart failure while on treatment. Mean left ventricular ejection fraction at baseline and at the end of THL were 63.6 % (N = 109, SD = 5.7) and 59.8 % (N = 98, SD = 8.1), respectively [mean change -3.95 % (N = 98, SD = 8.3), p < 0.001]. One hundred and two patients initiated post-AC treatment; of them, 31 % experienced grade 3 (no G4) diarrhea with lapatinib at 750 mg/day. The addition of lapatinib to paclitaxel and trastuzumab following AC does not add cardiac toxicity. Lapatinib dose of 750 mg/day in combination with standard chemotherapy plus trastuzumab has acceptable overall tolerability. | ||
| 710 |
_9303 _aServicio de Oncología Médica |
||
| 856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3392.pdf _ySolicitar documento |
||
| 942 |
_n0 _2ddc _cART |
||